1
|
Frappart PO and McKinnon PJ:
Ataxia-telangiectasia and related diseases. Neuromolecular Med.
8:495–511. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lavin MF: ATM: the product of the gene
mutated in ataxia-telangiectasia. Int J Biochem Cell Biol.
31:735–740. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Badalian LO and Kalinina LV: Lipid
metabolism disorder in ataxia-telangiectasia. Zh Nevropatol
Psikhiatr Im S S Korsakova. 76:665–669. 1976.(In Russian).
|
4
|
Su Y and Swift M: Mortality rates among
carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med.
133:770–778. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Schneider JG, Finck BN, Ren J, et al:
ATM-dependent suppression of stress signaling reduces vascular
disease in metabolic syndrome. Cell Metab. 4:377–389. 2006.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Mercer JR, Cheng KK, Figg N, et al: DNA
damage links mitochondrial dysfunction to atherosclerosis and the
metabolic syndrome. Circ Res. 107:1021–1031. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wu D, Yang H, Xiang W, et al: Heterozygous
mutation of ataxia-telangiectasia mutated gene aggravates
hypercholesterolemia in apoE-deficient mice. J Lipid Res.
46:1380–1387. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Watters D, Kedar P, Spring K, et al:
Localization of a portion of extranuclear ATM to peroxisomes. J
Biol Chem. 274:34277–34282. 1999. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kuljis RO, Chen G, Lee EY, Aguila MC and
Xu Y: ATM immunolocalization in mouse neuronal endosomes:
implications for ataxia-telangiectasia. Brain Res. 842:351–358.
1999. View Article : Google Scholar : PubMed/NCBI
|
10
|
Barlow C, Ribaut-Barassin C, Zwingman TA,
et al: ATM is a cytoplasmic protein in mouse brain required to
prevent lysosomal accumulation. Proc Natl Acad Sci USA. 97:871–876.
2000. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lim DS, Kirsch DG, Canman CE, et al: ATM
binds to beta-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci
USA. 95:10146–10151. 1998. View Article : Google Scholar : PubMed/NCBI
|
12
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Backer JM: Phosphoinositide 3-kinases and
the regulation of vesicular trafficking. Mol Cell Biol Res Commun.
3:193–204. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hunyady L, Baukal AJ, Gaborik Z, et al:
Differential PI 3-kinase dependence of early and late phases of
recycling of the internalized AT1 angiotensin receptor. J Cell
Biol. 157:1211–1222. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lemmon MA: Phosphoinositide recognition
domains. Traffic. 4:201–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gillooly DJ, Morrow IC, Lindsay M, et al:
Localization of phosphatidylinositol 3-phosphate in yeast and
mammalian cells. EMBO J. 19:4577–4588. 2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kutateladze TG: Phosphatidylinositol
3-phosphate recognition and membrane docking by the FYVE domain.
Biochim Biophys Acta. 1761:868–877. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Choi JH, Hong WP, Kim MJ, Kim JH, Ryu SH
and Suh PG: Sorting nexin 16 regulates EGF receptor trafficking by
phosphatidylinositol-3-phosphate interaction with the Phox domain.
J Cell Sci. 117:4209–4218. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Shetty S, Eckhardt ER, Post SR and van der
Westhuyzen DR: Phosphatidylinositol-3-kinase regulates scavenger
receptor class B type I subcellular localization and selective
lipid uptake in hepatocytes. Arterioscler Thromb Vasc Biol.
26:2125–2131. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kzhyshkowska J, Gratchev A, Brundiers H,
Mamidi S, Krusell L and Goerdt S: Phosphatidylinositide 3-kinase
activity is required for stabilin-1-mediated endosomal transport of
acLDL. Immunobiology. 210:161–173. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lavin MF, Khanna KK, Beamish H, Spring K,
Watters D and Shiloh Y: Relationship of the ataxia-telangiectasia
protein ATM to phosphoinositide 3-kinase. Trends Biochem Sci.
20:382–383. 1995. View Article : Google Scholar : PubMed/NCBI
|
22
|
Khanna KK, Yan J, Watters D, et al:
Defective signaling through the B cell antigen receptor in
Epstein-Barr virus-transformed ataxia-telangiectasia cells. J Biol
Chem. 272:9489–9495. 1997. View Article : Google Scholar : PubMed/NCBI
|
23
|
Chen A, Guo Z, Zhou L and Yang H: Hepatic
endosome protein profiling in apolipoprotein E deficient mice
expressing apolipoprotein B48 but not B100. J Bioanal Biomed.
2:100–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gamble W, Vaughan M, Kruth HS and Avigan
J: Procedure for determination of free and total cholesterol in
micro- or nanogram amounts suitable for studies with cultured
cells. J Lipid Res. 19:1068–1070. 1978.PubMed/NCBI
|
25
|
Martins IJ, Hone E, Chi C, Seydel U,
Martins RN and Redgrave TG: Relative roles of LDLr and LRP in the
metabolism of chylomicron remnants in genetically manipulated mice.
J Lipid Res. 41:205–213. 2000.PubMed/NCBI
|
26
|
Hui DY, Innerarity TL, Milne RW, Marcel YL
and Mahley RW: Binding of chylomicron remnants and beta-very low
density lipoproteins to hepatic and extrahepatic lipoprotein
receptors. A process independent of apolipoprotein B48. J Biol
Chem. 259:15060–15068. 1984.PubMed/NCBI
|
27
|
Corvera S: Phosphatidylinositol 3-kinase
and the control of endosome dynamics: new players defined by
structural motifs. Traffic. 2:859–866. 2001. View Article : Google Scholar : PubMed/NCBI
|
28
|
Clague MJ, Urbé S and de Lartigue J:
Phosphoinositides and the endocytic pathway. Exp Cell Res.
315:1627–1631. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Bakkenist CJ and Kastan MB: DNA damage
activates ATM through intermolecular autophosphorylation and dimer
dissociation. Nature. 421:499–506. 2003. View Article : Google Scholar : PubMed/NCBI
|
30
|
Magoori K, Kang MJ, Ito MR, et al: Severe
hypercholesterolemia, impaired fat tolerance, and advanced
atherosclerosis in mice lacking both low density lipoprotein
receptor-related protein 5 and apolipoprotein E. J Biol Chem.
278:11331–11336. 2003. View Article : Google Scholar
|